Abstract Background: Acute kidney injury (AKI) is a frequent complication in intensive care unit (ICU) patients and is associated with increased mortality and long-term kidney dysfunction. During the coronavirus disease 2019 (COVID-19) pandemic, high AKI rates have been reported in critically ill patients, but the magnitude and timing of any association in ICU populations remain uncertain-particularly when accounting for baseline severity of illness and missing pre-admission serum creatinine values. Methods: We analyzed 28,612 adult ICU stays (25,923 patients) from the Northwest Intensive Care Unit (NWICU) database between March 2020 and December 2022, excluding patients with end-stage kidney disease (ESKD). COVID-19 status was determined based on laboratory confirmation of SARS-CoV-2 infection when available, or otherwise by ICD-10 diagnosis codes, consistent with clinical practice during the study period. AKI was identified in two post-admission windows-0-48 hours and 0-7 days after ICU admission-using Kidney Disease: Improving Global Outcomes (KDIGO) creatinine-based criteria. Missing covariates were handled using multiple imputation by chained equations (MICE). We estimated the effect of COVID-19 on AKI risk using overlap-weighted logistic regression to balance pre-admission covariates, and repeated analyses adjusting for the Baseline Physiology Index (BPI), a composite severity score derived from the first 12 hours of ICU data. Results: Baseline creatinine was available in 57.7% of ICU stays. In the overlap-weighted cohort (effective sample size ≈ 11,600; maximum absolute standardized difference ≈ 0.01), the standardized 7-day AKI risk was 18.9% (95% confidence interval [CI] 18.5-19.4) in COVID-negative patients and 23.2% (95% CI 22.7-23.7) in COVID-positive patients, corresponding to a risk difference of +4.3 percentage points (pp) (95% CI 3.6-4.9) and an odds ratio (OR) of 1.29 (95% CI 1.24-1.35). Machine-learning-based propensity scores yielded similar results. At 48 hours, no meaningful difference was observed (+0.2 pp; OR 1.02, 95% CI 0.87-1.19). Adjusting for BPI attenuated the 7-day risk difference by approximately 19% in the full cohort and approximately 41% in the BPI-observed subset, but a substantial association persisted. Conclusions: In a large, ICU-admission-anchored cohort balanced on pre-admission traits, COVID-19 was linked to 4-5 extra AKI cases per 100 patients in the first week (not the first 48h). Adjustment for baseline physiologic severity attenuated this risk, indicating partial mediation by illness at presentation, while residual effects suggest other pathogenic pathways. The integrated approach-anchoring at admission, dual-rule KDIGO ascertainment, overlap weighting, and severity-attenuation-offers a robust framework for future COVID-AKI research.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study is a retrospective analysis of de-identified ICU patient records from the Northwest Intensive Care Unit (NWICU) database, available through PhysioNet. Access was obtained after completing the required online research ethics course and registering for controlled access. As such, the work involves the use of human data but did not use simulated data or data that were freely and publicly available prior to the study. No identifiable information was available to the researchers, and the dataset was provided under existing PhysioNet ethical and data-use approvals.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes